Table 1 Trials evaluating possible utility of routine brain imaging among patients with breast cancer
NCT | PI | Year of study initiation | Country | Patient population | Frequency of brain imaging | Investigation for brain metastases | Status |
|---|---|---|---|---|---|---|---|
NCT05115474 | Ahmed | 2021 | USA | Metastatic BC | Baseline and 6 m or at first extra-cranial progression | MRI | Recruiting |
NCT04030507 | Aizer | 2019 | USA | Inflammatory BC or Metastatic HER2+ve and TNBC | Inflammatory BC: Baseline only Metastatic HER2+ and TNBC: baseline and at first extra-cranial progression | MRI | Recruiting |
NCT03881605 | Jerzak | 2018 | Canada | Metastatic HER2+ve and TNBC | Baseline, 4 m, 8 m, 12 m | MRI | Completed |
NCT03617341 | Sohn | 2018 | South Korea | Metastatic or unresectable HER2+ve and TNBC | At initial diagnosis, first- and second-line treatment failure | MRI | Unknown |
NCT05130840 | Malani | 2021 | USA | Metastatic HER2+ve (with 1 or more lines of HER2-directed therapy) or stage II-III HER2+ve BC | MRI and lumbar puncture at 2 time points 6 months apart (+/- 8 weeks). | MRI + LP | Recruiting |
NCT00398437 | Lebrun | 2006 | Belgium | Metastatic HER2+ve | Baseline and every 4 m | MRI | Unknown |
NCT02706964 | O’Dell | 2016 | USA | High risk TNBC | Baseline | MRI | Completed |
HER2-CNS SURVEILLANCE | Palmieri & Meade | 2023 | UK | Metastatic HER2+ve BC | Baseline and every 6 m | MRI | Ongoing |
